News und Analysen
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche
Swiss Life increases net profit, cash remittance and dividend in 2023 – real estate market environment dampens fee result
Swiss Life increases net profit, cash remittance and dividend in 2023 – real estate market environment dampens fee result
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza
Swiss Life: change to the Group Executive Board in 2024
Swiss Life: change to the Group Executive Board in 2024
Swiss Life continues to grow in the first nine months of 2023
Swiss Life continues to grow in the first nine months of 2023
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
Capital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
Capital Markets Day 2023:
New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023
Swiss Life increases both profit from operations and net profit on a comparable basis in the first half of 2023
Swiss Life increases both profit from operations and net profit on a comparable basis in the first half of 2023
Markus Leibundgut, CEO of Swiss Life Switzerland, has fallen ill
Markus Leibundgut, CEO of Swiss Life Switzerland, has fallen ill
Swiss Life publishes key financial figures for the 2022 financial year in accordance with the new IFRS accounting standards
Swiss Life publishes key financial figures for the 2022 financial year in accordance with the new IFRS accounting standards
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
Swiss Life increases fee income by 7% in the first quarter of 2023
Swiss Life increases fee income by 7% in the first quarter of 2023
Q1 2023 Qualitative Update: Business Performance In Line With Full-Year Trajectory
Q1 2023 Qualitative Update: Business Performance In Line With
Full-Year Trajectory
Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
Swiss Life publishes financial condition report – strong solvency continues
Swiss Life publishes financial condition report – strong solvency continues
Swiss Life shareholders approve all resolutions proposed by the Board of Directors
Swiss Life shareholders approve all resolutions proposed by the Board of Directors
Lonza Launches Share Buyback Program of up to CHF 2 Billion
Lonza Launches Share Buyback Program of up to CHF 2 Billion
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)